Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

Hims & Hers’ second-quarter revenue rose nearly 40% year over year to more than $753 million, including U.S. revenue growth of 16% to $622 million and international revenue above 17-fold growth to $131 million. AI handled about 80% of questions in the new experience and cut nonclinical support tasks nearly 50%, while adjusted gross margin fell about 6 percentage points sequentially to 64%; operating cash flow was negative $36 million and free cash flow negative $68 million. Management targets at least $600 million in international revenue in 2026, but peptide commercialization depends on FDA rulemaking; consensus 2026 revenue is $3.22 billion while the loss-per-share estimate worsened 185.7% over the past 30 days.

Analysis

The key issue is growth quality, not demand: HIMS is shifting toward branded therapies and international sales where revenue can scale faster than gross profit and cash conversion. If mix keeps gross margin below its prior range while receivables and inventory absorb cash, headline growth may not support the same valuation multiple. The $400 million receivables facility is a liquidity buffer, not evidence that working-capital intensity has normalized.

Strategically, HIMS’s platform could widen access and improve adherence, but pharmaceutical partners retain control of the products and economics. Wider availability of branded GLP-1s can validate the channel while also making HIMS more substitutable—patients may migrate to manufacturer or other provider channels. Novo Nordisk benefits from additional reach, but the article does not establish incremental economics for either party. AI cost savings are plausible, yet engagement from an early user cohort is not proof of platform-wide retention gains; clinical oversight and compliance remain constraints.

Near term (days to weeks), estimate revisions and cash-flow expectations matter more than the peptide option. Over 1–3 months, test management’s promised second-half FCF recovery against inventory, receivables and gross-margin trends. Over 6–18 months, the thesis hinges on whether international scale and retention offset structurally lower product margins. FDA rulemaking is a binary, timing-sensitive catalyst; do not capitalize peptide revenue before clarity. Contrarian angle: the growth narrative may underweight cash conversion, but a bearish position is premature if cohorts retain well and FCF rebounds. No valuation or current price data supports a target.

Key Decisions for Investors

• Keep HIMS exposure sized as a growth position, not a proven operating-leverage story. Reassess after the next report: require improving free cash flow alongside revenue growth and stabilization in gross margin before adding.
• Watch quarterly receivables, inventory and cash conversion. If FCF remains negative into the second half or margin compression continues without evidence of better retention, reduce exposure; a clear FCF rebound with stable cohort retention would falsify the cautious view.
• For GLP-1 exposure, consider a conditional relative-value expression favoring Novo Nordisk over HIMS rather than an outright HIMS short: the former owns the therapy economics while HIMS bears channel, mix and working-capital execution risk. Validate relative valuation and drug/channel outlook before entry.
• Treat peptide-related upside as unpriced optionality, not a base-case catalyst. Revisit only after final FDA rulemaking specifies permissible products and timing; adverse or delayed guidance would remove this potential catalyst.